MNDA pin

IHC

MNDA

Alternate Test Names:
Myeloid cell Nuclear Differentiation Antigen

Methodology: IHC

Clinical Significance:
Although the expression of MNDA was initially thought to be restricted to the myelomonocytic lineage, several studies have shown the expression of this protein by normal and neoplastic B lymphocytes. MNDA has been shown to be expressed in splenic marginal zone lymphomas, mantle cell lymphomas, nodal marginal zone lymphomas and hairy cell leukemia.

MNDA (clone 253A) will be used as part of a larger IHC panel to help distinguish marginal zone B cell lymphoma (MZL) from follicle center-derived B cell lymphoma, particularly CD10-negative FL.

Subcellular Localization: Almost entirely Nuclear

Organ: Blood/Bone Marrow, Lymph Node / Spleen

Disease State: Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL), Hairy Cell Leukemia, Mantle Cell Lymphoma, Marginal Zone/MALT Lymphoma

CPT Code(s): 88342 or 88341 (reference only; CPTs may vary)

Turnaround Time: Within 1-2 business days of receipt

Schedule: Monday - Friday

Specimen Requirements:
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR -
• 1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm

Tech Only